Drugs / Pavise ECMR
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07462533 Comparator | Mar → Jul 2026 overdue | cutis laxa | Goldman, Butterwick, Fitzpatrick and Groff | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pavise ECMR | “Pavise ECMR (extracellular matrix restore) serum regimen combined with laser treatment” NCT07462533 ↗ |